Literature DB >> 10576448

Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease?

E Kienzl1, K Jellinger, H Stachelberger, W Linert.   

Abstract

The mechanisms leading to degeneration of melanized dopaminergic neurons in the brain stem, and particularly in the substantia nigra zona compacta (SNZC) in patients with Parkinson's disease (PD) are still unknown. Demonstration of increased iron Fe(III) in SNZC of PD brain has suggested that Fe-melanin interaction may contribute to oxidative neuronal damage. Energy dispersive X-ray electron microscopic analysis of the cellular distribution of trace elements revealed significant Fe-peaks, similar to those of a synthetic melanin-Fe(III) complex in intracytoplasmic electron-dense neuromelanin granules of SNZC neurons, with highest levels in a case of PD and Alzheimer's disease (AD). No Fe increase was found in Lewy bodies or in SN neurons of control specimens. The relevance of chemical reactions of dopamine (DA), 5-hydroxydopamine (5-OHDA), and 6-hydroxydopamine (6-OHDA) with Fe(III) and with dioxygen for the pathogenesis of PD was investigated. An initiating mechanism related to interaction between Fe and neuromelanin is suggested which results in accumulation of Fe(III) and a continuous production of cytotoxic species inducing a cascade of pathogenic reactions ultimately leading to neuronal death.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576448     DOI: 10.1016/s0024-3205(99)00458-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  17 in total

1.  Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+).

Authors:  Francisco J Gómez; Pabla Aguirre; Christian Gonzalez-Billault; Marco T Núñez
Journal:  J Neural Transm (Vienna)       Date:  2010-10-02       Impact factor: 3.575

2.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 3.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

Review 4.  Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?

Authors:  A Barzilai; E Melamed; A Shirvan
Journal:  Cell Mol Neurobiol       Date:  2001-06       Impact factor: 5.046

5.  Effects of fetal bovine serum on ferrous ion-induced oxidative stress in pheochromocytoma (PC12) cells.

Authors:  J H Song; M S Harris; S H Shin
Journal:  Neurochem Res       Date:  2001-04       Impact factor: 3.996

6.  Time dependent effects of 6-OHDA lesions on iron level and neuronal loss in rat nigrostriatal system.

Authors:  Jun Wang; Hong Jiang; Jun-Xia Xie
Journal:  Neurochem Res       Date:  2004-12       Impact factor: 3.996

7.  Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system.

Authors:  Ambreena Siddiq; Issam A Ayoub; Juan C Chavez; Leila Aminova; Sapan Shah; Joseph C LaManna; Stephanie M Patton; James R Connor; Robert A Cherny; Irene Volitakis; Ashley I Bush; Ingrid Langsetmo; Todd Seeley; Volkmar Gunzler; Rajiv R Ratan
Journal:  J Biol Chem       Date:  2005-10-13       Impact factor: 5.157

8.  Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients.

Authors:  Dimitri Hautot; Quentin A Pankhurst; Chris M Morris; Andrew Curtis; John Burn; Jon Dobson
Journal:  Biochim Biophys Acta       Date:  2006-10-06

Review 9.  The 6-hydroxydopamine model of Parkinson's disease.

Authors:  Nicola Simola; Micaela Morelli; Anna R Carta
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

Review 10.  Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease.

Authors:  Manfred Gerlach; Kay L Double; Dorit Ben-Shachar; Luigi Zecca; Moussa B H Youdim; Peter Riederer
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.